Dr. Bonvalot on the Long-Term Safety of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma

Video

Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.

Sylvie Bonvalot, MD, PhD, HDR, the head of sarcoma surgery at Institut Curie, in Paris, France, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial (NCT02379845).

There were no significant differences in serious adverse effects (AEs) related to radiotherapy between both groups enrolled on the study, according to Bonvalot. In total, 11.2% of patients who received NBTXR3 plus radiotherapy, and 13.3% of those who received radiotherapy alone, experienced serious AEs related to radiotherapy.

In soft tissue sarcoma, very often in patients with advanced-stage disease, surgical morbidities leading to rehospitalization are common. The rate of hospitalization due to serious AEs related to surgery was 15.7% and 24.4% in both groups, respectively, which was not a significant difference, Bonvalot says.

The findings are interesting, as previous data indicated that grade 3 morbidities leading to rehospitalization or reoperation due to perioperative radiotherapy occurred in approximately 30% of patients, Bonvalot explains. The rate of hospitalization was less in the Act.In.Sarc trial vs older findings, as well as less in the NBTXR3 cohort, Bonvalot concludes.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center